No Data
US Stock MarketDetailed Quotes
ADCT ADC Therapeutics
Watchlist
1.070
+0.040+3.88% Close 12/06 16:00 ET
1.0700.0000.00%
Pre 05:24 ET
1.070High1.000Low215.89KVolume
1.010Open1.030Pre Close226.37KTurnover0.43%Turnover RatioLossP/E (TTM)86.29MMarket Cap5.75052wk HighLossP/E (Static)80.64MShares0.36052wk Low-1.59P/B53.86MFloat Cap56.590Historical High--Dividend TTM50.34MShs Float0.360Historical Low--Div YieldTTM6.79%Amplitude1.048Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About ADC Therapeutics Company
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
News
ABBV.US (ABBV.US) spent $10 billion to acquire Immunogen (IMGN.US) ADC drug developers, and most of the stock prices of drug developers rose
Immunogen closed nearly 83% higher on Thursday and AbbVie closed nearly 3% higher. Shares of other biotech companies developing ADC drugs also rose.
AbbVie-Immunogen Buyout Deal Lifts ADC-focused Biotechs
Analyst Expectations for ADC Therapeutics's Future
Within the last quarter, ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings22000Last 30D100001M Ago010002M